CORBF.US Global Cord Blood Corporation
- Market cap
- USD 141M
- P/E
- 2.1x
- P/B
- 0.24x
- ROE
- 55.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2022.
Is CORBF.US undervalued?
Graham numberThe Graham number of Global Cord Blood Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Global Cord Blood Corporation fundamental analysis
No fundamental analysis for Global Cord Blood Corporation yet.
Global Cord Blood Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Global Cord Blood Corporation
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Gl…
Full company profileGlobal Cord Blood Corporation financial statements
2022 annualized: Fiscal year 2022 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2022, the balance sheet is the latest quarter. Figures change when the annual report is published.
Global Cord Blood Corporation annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 526M | 573M | 635M | 663M | 760M | 937M | 987M | 1.22B | 1.16B | 1.24B | 1.19B |
| Gross Profit | 420M | 467M | 505M | 518M | 617M | 755M | 801M | 1.03B | 981M | 1.06B | 1.02B |
| Operating Income | 209M | 232M | 235M | 191M | 265M | 280M | 382M | 559M | 545M | 609M | 569M |
| EBITDA | 257M | 297M | 306M | 299M | 334M | 354M | 405M | 572M | 518M | 629M | 569M |
| Net Income | 112M | 132M | 107M | 91.0M | 126M | 237M | 291M | 471M | 508M | 501M | 427M |
| EPS | 1.49 | 1.60 | 1.36 | 1.25 | 1.59 | 1.99 | 2.40 | 3.87 | 4.18 | 4.12 | 0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 2.99B | 3.63B | 4.12B | 4.69B | 5.18B | 5.84B | 6.55B | 7.22B | 7.91B | 8.53B | 1.35B |
| Total Liabilities | 1.74B | 2.19B | 2.58B | 2.97B | 3.34B | 2.73B | 3.13B | 3.33B | 3.52B | 3.65B | 576M |
| Shareholders' Equity | 1.24B | 1.44B | 1.54B | 1.71B | 1.84B | 3.12B | 3.42B | 3.89B | 4.39B | 4.88B | 770M |
| Cash & Short-term Investments | 1.49B | 1.88B | 2.44B | 3.01B | 3.51B | 4.25B | 5.00B | 5.47B | 6.08B | 6.66B | 1.05B |
| Total Debt | 802M | 838M | 876M | 966M | 1.03B | 0.00 | 0.00 | 3.50M | 1.78M | 147K | 23.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 579M | 536M | 595M | 581M | 638M | 819M | 792M | 624M | 631M | 614M | -1.31M |
| Capital Expenditure | 226M | 150M | 37.8M | 16.6M | 24.7M | 67.1M | 30.7M | 24.2M | 20.9M | 19.8M | 0.00 |
| Free Cash Flow | 352M | 386M | 557M | 564M | 613M | 752M | 761M | 600M | 610M | 594M | -1.31M |
| Ratios | |||||||||||
| ROE | 9.1% | 9.2% | 7.0% | 5.3% | 6.8% | 7.6% | 8.5% | 12.1% | 11.6% | 10.3% | 55.5% |
| ROA | 3.8% | 3.6% | 2.6% | 1.9% | 2.4% | 4.1% | 4.4% | 6.5% | 6.4% | 5.9% | 31.7% |
| Net Profit Margin | 21.4% | 23.0% | 16.9% | 13.7% | 16.6% | 25.3% | 29.5% | 38.5% | 43.8% | 40.3% | 35.9% |
| Debt to Equity | 0.65x | 0.58x | 0.57x | 0.56x | 0.56x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Global Cord Blood Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 31, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | CNY 18.2M | 0.15 | 6.2% |
| 2018 | CNY 0.03 | 0.00 | 0.0% |
| 2017 | CNY 0.01 | 0.00 | 0.0% |
| 2016 | CNY 0.02 | 0.00 | 0.0% |
| 2015 | - | - | - |
| 2014 | CNY 254K | 0.00 | 0.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Global Cord Blood Corporation
- Insiders 0.00%
- Institutions 13.40%
- Public & others 86.60%
- Shares outstanding 134M
- Free float 117M
Top funds holding CORBF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Man GLG Event Driven Alternative IN USD | 1.07M | 0.80% | +0.65% | Mar 2023 |
| Wealth Invest L&P Dividende Fond | 163K | 0.12% | 0.00% | Jun 2023 |
| Wealth Invest L&P Global Value Fond | 161K | 0.12% | 0.00% | Jun 2023 |
| MW Asset Management MW Optimum CR-P Cap | 116K | 0.09% | 0.00% | Nov 2022 |
| Parametric International Equity I | 29.6K | 0.02% | 0.00% | Apr 2023 |
| Avantis® Emerging Markets Equity ETF | 18.6K | 0.01% | 0.00% | Jun 2023 |
| Cinvest Azero Global FI | 10.0K | 0.01% | 0.00% | May 2023 |
| Base Inv Macro Dynamic EUR | 7.00K | 0.01% | 0.00% | May 2023 |
| Northern Small Cap Core K | 6.35K | 0.00% | 0.00% | Mar 2023 |
| Avantis® Emerging Markets Equity Instl | 2.02K | 0.00% | 0.00% | May 2023 |
Top institutions holding CORBF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Oasis Management Co. Ltd | 6.80M | 5.08% | 0.00% | Mar 2023 |
| Renaissance Technologies Corp | 2.35M | 1.75% | 0.00% | Mar 2023 |
| Man Group PLC | 1.80M | 1.35% | 0.00% | Mar 2023 |
| BlueCrest Capital Management Ltd. | 749K | 0.56% | 0.00% | Mar 2023 |
| Quinn Opportunity Partners LLC | 324K | 0.24% | 0.00% | Mar 2023 |
| IsZo Capital Management LP | 279K | 0.21% | 0.00% | Mar 2023 |
| Natixis Advisors, LLC. | 201K | 0.15% | 0.00% | Mar 2023 |
| Bank of America Corp | 176K | 0.13% | 0.00% | Mar 2023 |
| Morgan Stanley - Brokerage Accounts | 87.1K | 0.07% | 0.00% | Mar 2023 |
| Benjamin F. Edwards & Company, Llc | 59.1K | 0.04% | 0.00% | Mar 2023 |
| Northern Trust Corp | 31.6K | 0.02% | 0.00% | Mar 2023 |
| Moneta Group Investment Advisors Inc | 26.1K | 0.02% | 0.00% | Mar 2023 |
| American Century Companies Inc | 20.6K | 0.02% | 0.00% | Mar 2023 |
| Susquehanna International Group, LLP | 13.3K | 0.01% | 0.00% | Mar 2023 |
| Marshall Wace Asset Management Ltd | 12.3K | 0.01% | 0.00% | Mar 2023 |
| CLARK FINANCIAL SERVICES GROUP INC /BD | 12.3K | 0.01% | 0.00% | Mar 2023 |
| Two Sigma Advisers, LLC | 11.4K | 0.01% | 0.00% | Mar 2023 |
| Citadel Advisors Llc | 10.8K | 0.01% | 0.00% | Mar 2023 |
| UMB Bank NA | 3.98K | 0.00% | 0.00% | Mar 2023 |
| UBS Group AG | 1.24K | 0.00% | 0.00% | Mar 2023 |
Global Cord Blood Corporation company profile
- Company name
- Global Cord Blood Corporation
- Ticker
- CORBF.US
- Exchange
- USA Stocks
- Listed since
- May 9, 2007
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 1,202
- Fiscal year end
- March
- Address
- Bank of China Tower, Central, Hong Kong
- Phone
- 852 3605 8180
- Website
- globalcordbloodcorp.com
About Global Cord Blood Corporation
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Global Cord Blood Corporation management
5- Ms. Ting ZhengCEO & CEO of Beijing Division · born 1972
- Mr. Bing Chuen Chen C.F.A.Chief Financial Officer · born 1976
- Ms. Xin XuChief Technology Officer · born 1954
- Ms. Rui ArashiyamaChief Executive Officer of Guangdong & Zhejiang Divisions · born 1959
- Ms. Cathy BaiVice President of Corporate Finance